MedTrace Logo

Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity

NCT06197295 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2025-05-09

No results posted yet for this study

Summary

To investigates the effects of combined pharmacotherapy with solifenacin and mirabegron versus solifenacin with vaginal estrogen cream in women with detrusor overactivity.

Conditions

  • Urinary Bladder, Overactive
  • Effect of Drug

Interventions

DRUG

Solifenacin with vaginal estrogen cream

Solifenacin 5mg with vaginal conjugated equine estrogen (CEE) 0.625 mg

DRUG

Combination pharmacotherapy

Solifenacin 5mg and Mirabegron 25mg

Sponsors & Collaborators

  • Mackay Memorial Hospital

    lead OTHER

Principal Investigators

  • Hui-Hsuan Lau, MD · Mackay Memorial Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
90 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-16
Primary Completion
2026-06-30
Completion
2026-12-31
FDA Drug
Yes

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06197295 on ClinicalTrials.gov